The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin

Steven L. Flamm, Kimberly Brown, Hani M. Wadei, Robert S. Brown, Marcelo Kugelmas, Milagros Samaniego‐Picota, Patrizia Burra, Fred Poordad, Sammy Saab – 12 April 2021 – Acute kidney injury (AKI) in the setting of cirrhosis (hepatorenal syndrome [HRS]–AKI) is a severe and often fatal complication of end‐stage liver disease. The goals of treatment are to reverse renal failure and prolong survival in patients who are critically ill. However, interventions have limited efficacy, and mortality rates remain high.

Subscribe to